Wegener's granulomatosis

Thorax

Volumn 54, Issue 7, 1999, Pages 629-637

  Langford, Carol A ^a   Hoffman, Gary S ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

BONE MARROW SUPPRESSION; CLINICAL FEATURE; GLOMERULONEPHRITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SUBGLOTTIC STENOSIS; TRANSITIONAL CELL CARCINOMA; WEGENER GRANULOMATOSIS; ADULT; BLOOD; DISEASE PREDISPOSITION; DRUG COMBINATION; FEMALE; LEUKOCYTE ACTIVATION; MALE; PREVALENCE;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; DISEASE SUSCEPTIBILITY; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEUTROPHIL ACTIVATION; PREVALENCE; WEGENER GRANULOMATOSIS;

EID: 0033026088     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.7.629     Document Type: Review

References (68)

1. 1 Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis. Arthritis Rheum 1996;39:87-92.
2. 2 Duna GF, Cotch MF, Galperin C, et al. Wegener's granulomatosis: role of environmental exposures. Clin Exp Rheumatol 1998;16:527-32.
3. 3 Hoffman GS, Kerr GS, Leavin RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-94.
4. 4 Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996;39:1754-60.
5. 5 Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
6. 6 Daum TE, Specks U, Colby TV, et al. Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med 1995;151:522-6.
7. 7 Haynes BF, Fishman ML, Fauci AS, et al. The ocular manifestations of Wegener's granulomatosis. Am J Med 1977;63: 131-41.
8. 8 Nishino H, Rubino FA, DeRemee RA, et al. Neurological involvement in Wegener's granulomatosis. Ann Neurol 1993;33:4-9.
9. 9 Walton E. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958;2:265-70.
10. 10 Devaney KO, Travis WD, Hoffman GS, et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990;14:555-64.
11. 11 Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991;15:315-33.
12. 12 Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? BMJ 1982;285:606.
13. 13 van der Woude FJ, Lobatto S, Permin H, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;i:425-9.
14. 14 Niles JL, McCluskey RT, Ahmad MF, et. al. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 1989;74:1888-93.
15. 15 Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vusculitis and idiopathic necrotizing and crescenric glomerulonephritis. N Engl J Med 1988;318:1651-7.
16. 16 Gross W. Antineutrophil cytoplasmic autoantibody testing in vasculitides. Rheum Dis Clin North Am 1995;4:987-1011.
17. 17 Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149: 2461-5.
18. 18 Nolle B, Specks U, Ludemann J, et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med 1989;111:28-40.
19. 19 Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 1995;123:925 32.
20. 20 Davenport A. False positive perinuclear and cytoplasmic anti-neutrophil cytoplasmic antibody results leading to misdiagnosis of Wegener's granulomatosis and/or microscopic polyarteritis. Clin Nephrol 1992;37:124-30.
21. 21 Langford CA. The diagnostic utility of c-ANCA in Wegener's granulomatosis. Clev Clin J Med 1998;65:135-40.
22. 22 Cohen Tervaert JW, Huitem MG, Hene RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on anti-neutrophil cytoplasmic antibody titer. Lancet 1990; 336:709-11.
23. 23 Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993;36:365-71.
24. 24 Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967;67:393-8.
25. 25 Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
26. 26 Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:1120-7.
27. 27 Hoffman GS, Leavitt RY, Fleisher TA, et al. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403 10.
28. 28 Reinhold KE, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994;37:919-24.
29. 29 Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
30. 30 Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-9.
31. 31 Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
32. 32 Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997;23-841-53.
33. 33 de Groot K, Reinhold-Keller E, Tatsis E, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39:2052-61.
34. 34 Allen NB, Caldwell DS, Rice JR, et al. Cyclosporin A therapy for Wegener's granulomatosis. Adv Exp Med Biol 1993;336:473-6.
35. 35 Lockwood CM. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996;104(Suppl 1):77-82.
36. 36 Richter C, Schnabel A, Csernok E, et al. Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv Exp Med Biol 1993;336:487-8.
37. 37 DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985;60:27-32.
38. 38 Israel HL. Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch Intern Med 1988;148: 2293-5.
39. 39 Stegeman CA, Cohen Tervaert JW, deJong PE, et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996;335:16-20.
40. 40 Hauschild S, Schmitt W, Csernok E, et al. ANCA in systemic vasculitides, collagen vascular disease, rheumatic disorders and inflammatory bowel diseases. In: Gross WL, ed. ANCA-associated vasculitides: immunological and clinical aspects. New York: Plenum Press, 1993: 245-51.
41. 41 Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998;53: 743-53.
42. 42 Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521-37.
43. 43 Charles LA, Caldas MLR, Falk RJ, et al. Antibodies against granule proteins activate neutrophils in vitro. J Leukocyte Biol 1991;50:539-46.
44. 44 Csernok E, Ernst M, Schmitt W, et al. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994;95:244-50.
45. 45 Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4115-9.
46. 46 Savage COS, Gaskin G, Pusey CD, et al. Antineutrophil cytoplasmic antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens. Exp Nephrol 1993;1:190-5.
47. 47 Ewert BH, Becker ME, Jennette JC, et al. Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells. Renal Failure 1995;17:125-33.
48. 48 Berger SP, Seelen MA, Hiemstra PS, et al. Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephol 1996;7:694-701.
49. 49 de Brandt M, Ollivier V, Meyer O, et al. Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells. Arthritis Rheum 1997;40:2030-8.
50. 1-antitrypsin, and Fcγ receptors. J Clin Invest 1997;100:1416-24.
51. 51 Mayet WJ, Schwarting A, Orth T, et al. Signal transduction pathways of membrane expression of proteinase-3 (PR-3) in human endothelial cells. Eur J Clin Invest 1997;27:893-9.
52. 52 Mayet WJ, Meyer zum Buschenfelde KH. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993;94:440-6.
53. 53 Mayet WJ, Schwarting A, Meyer zum Buschenfelde KH. Cytotoxic effects of antibodies to proteinase 3 (c-ANCA) on human endothelial cells. Clin Exp Immunol 1994;97: 458-65.
54. 54 King WJ, Adu D, Daha MR, et al. Endothelial cells and renal epithelial cells do not express the Wegener's antoantigen, proteinase 3. Clin Exp Immunol 1995;102:98-105.
55. 55 Barth J, Petermann W, Kreipe H, et al. Bronchoalveoläre lavage ber Wegenerscher granulomatose. Pneumologie 1991; 45:570-4.
56. 56 Hoffman GS, Sechler JMG, Gallin JI, et al. Bronchoalveolar lavage analysis in Wegener's granulomatosis. Am Rev Respir Dis 1991;143:401-7.
57. 57 Baltaro RJ, Hoffman GS, Sechler JMG, et al. Immunoglobulin G antineutrophil cytoplasmic antibodies are produced in the respiratory tract of patients with Wegener's granulomatosis. Am Rev Respir Dis 1991;143:275-8.
58. 58 Minick CR, Fabricant CG, Fabricant J, et al. Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol 1979;96:673-706.
59. 59 Weck KE, Dal Canto AJ, Gould JD, et al. Murine γ-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-γ responsiveness; a new model for virus-induced vascular disease. Nature Med 1997;3:1346-57.
60. 60 Presti RM, Pollock JL, Dal Canto AJ, et al. Interferon γ regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med 1998;188:577-88.
61. 61 Hadlow WJ, Race RE, Kennedy RC. Comparative pathogenicity of four strains of Aleutian disease virus for pastel and sapphire mink. Infect Immunol 1983;41:1016-23.
62. 62 Henson JB, Gorham JR. Animal model of human disease. Am J Pathol 1973;71:1345-8.
63. 63 Grau G, Roux-Lombard P, Gysler C, et al. Serum cytokine changes in systemic vasculitis. Immunology 1989;68:196-8.
64. 64 Arimura Y, Minoshima S, Kamiya Y, et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 1993; 40:256-64.
65. 65 Deguchi Y, Shibata N, Kishimoto S. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 1990;81:311-4.
66. 66 Noronha IL, Kruger C, Andrassy K, et al. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993;43:682-92.
67. 67 Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91.
68. 68 Ludviksson BR, Sneller MC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602-9.